CN112544989A - A composition with muscle protecting effect - Google Patents
A composition with muscle protecting effect Download PDFInfo
- Publication number
- CN112544989A CN112544989A CN202011511533.8A CN202011511533A CN112544989A CN 112544989 A CN112544989 A CN 112544989A CN 202011511533 A CN202011511533 A CN 202011511533A CN 112544989 A CN112544989 A CN 112544989A
- Authority
- CN
- China
- Prior art keywords
- parts
- powder
- protein
- muscle
- soybean protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000003205 muscle Anatomy 0.000 title claims abstract description 25
- 239000000203 mixture Substances 0.000 title claims abstract description 16
- 230000002633 protecting effect Effects 0.000 title description 2
- 239000000843 powder Substances 0.000 claims abstract description 36
- 235000001674 Agaricus brunnescens Nutrition 0.000 claims abstract description 20
- 108010073771 Soybean Proteins Proteins 0.000 claims abstract description 20
- 235000019710 soybean protein Nutrition 0.000 claims abstract description 19
- 239000002994 raw material Substances 0.000 claims abstract description 15
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 14
- 230000000694 effects Effects 0.000 claims abstract description 10
- 235000013406 prebiotics Nutrition 0.000 claims abstract description 10
- 102000007544 Whey Proteins Human genes 0.000 claims abstract description 7
- 108010046377 Whey Proteins Proteins 0.000 claims abstract description 7
- 235000021119 whey protein Nutrition 0.000 claims abstract description 7
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 7
- 229920001202 Inulin Polymers 0.000 claims description 5
- 238000000855 fermentation Methods 0.000 claims description 5
- 230000004151 fermentation Effects 0.000 claims description 5
- 229940029339 inulin Drugs 0.000 claims description 5
- 235000010469 Glycine max Nutrition 0.000 claims description 3
- 244000068988 Glycine max Species 0.000 claims description 3
- 239000002131 composite material Substances 0.000 claims description 3
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 claims description 3
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims description 3
- 229940107187 fructooligosaccharide Drugs 0.000 claims description 3
- 241000186605 Lactobacillus paracasei Species 0.000 claims description 2
- 241000191996 Pediococcus pentosaceus Species 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 abstract description 15
- 108090000623 proteins and genes Proteins 0.000 abstract description 15
- 235000018102 proteins Nutrition 0.000 abstract description 14
- 235000013305 food Nutrition 0.000 abstract description 8
- 230000009469 supplementation Effects 0.000 abstract description 4
- 230000002195 synergetic effect Effects 0.000 abstract description 3
- 238000009776 industrial production Methods 0.000 abstract description 2
- 239000000126 substance Substances 0.000 abstract description 2
- 230000009982 effect on human Effects 0.000 abstract 1
- 230000000052 comparative effect Effects 0.000 description 17
- 208000029549 Muscle injury Diseases 0.000 description 9
- 241000252212 Danio rerio Species 0.000 description 8
- 229930003316 Vitamin D Natural products 0.000 description 8
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 8
- 235000019166 vitamin D Nutrition 0.000 description 8
- 239000011710 vitamin D Substances 0.000 description 8
- 150000003710 vitamin D derivatives Chemical class 0.000 description 8
- 229940046008 vitamin d Drugs 0.000 description 8
- 235000016709 nutrition Nutrition 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 5
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 230000035764 nutrition Effects 0.000 description 4
- 102000015636 Oligopeptides Human genes 0.000 description 3
- 108010038807 Oligopeptides Proteins 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 235000012631 food intake Nutrition 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 208000001076 sarcopenia Diseases 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 102000004407 Lactalbumin Human genes 0.000 description 2
- 108090000942 Lactalbumin Proteins 0.000 description 2
- 208000005374 Poisoning Diseases 0.000 description 2
- 241000209140 Triticum Species 0.000 description 2
- 235000021307 Triticum Nutrition 0.000 description 2
- 230000002009 allergenic effect Effects 0.000 description 2
- 208000003455 anaphylaxis Diseases 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000834 fixative Substances 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 231100000572 poisoning Toxicity 0.000 description 2
- 230000000607 poisoning effect Effects 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 229940116540 protein supplement Drugs 0.000 description 2
- 235000005974 protein supplement Nutrition 0.000 description 2
- 239000012192 staining solution Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010002216 Anaphylactoid reaction Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 108010010256 Dietary Proteins Proteins 0.000 description 1
- 102000015781 Dietary Proteins Human genes 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 206010020590 Hypercalciuria Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000008934 Muscle Proteins Human genes 0.000 description 1
- 108010074084 Muscle Proteins Proteins 0.000 description 1
- 208000023178 Musculoskeletal disease Diseases 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000008047 antioxidant nutrient Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 235000008242 dietary patterns Nutrition 0.000 description 1
- 235000021245 dietary protein Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 235000020978 long-chain polyunsaturated fatty acids Nutrition 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000009525 mild injury Effects 0.000 description 1
- 230000009526 moderate injury Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 208000017445 musculoskeletal system disease Diseases 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000001223 reverse osmosis Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 229940001941 soy protein Drugs 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L31/00—Edible extracts or preparations of fungi; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
The invention discloses a composition with a muscle protection effect, which comprises the following raw materials in parts by weight: 11.13-100.09 parts of fermented soybean protein peptide powder, 10.99-98.83 parts of whey protein, 5.08-45.68 parts of prebiotics and 0.31-2.81 parts of mushroom powder, wherein the purity of the mushroom powder is 10%. The invention uses the fermented soybean protein peptide powder with low allergenicity, and the mushroom powder has obvious synergistic protection effect on human muscle when being combined with the fermented soybean protein, the whey protein and the prebiotics substances. The raw materials in the formula are common food raw materials, so that the food is suitable for all people needing protein supplementation, and large-scale industrial production can be realized.
Description
Technical Field
The invention discloses a food composition with a muscle protection effect, and belongs to the technical field of food processing.
Background
With increasing age and decreasing energy demand, food and energy intake drops by an average of 25% from age 40 to age 70. Low food intake and a monotonous diet put the elderly at risk because as the total food intake decreases, the intake of most nutrients also decreases accordingly. In a consolidated analysis of data from 12 countries, approximately two thirds of the elderly participating in the study were determined to have nutritional problems or malnutrition.
In 2018, the European osteoporosis, osteoarthritis and musculoskeletal disease Clinical and economic problems Association (ESCEO) working group multiple experts published an important review article in the journal of Clinical Nutrition entitled "Does Nutrition play a role in the prevention and treatment of sarcopenia" (ROBINSON S M, REGISTER J Y, RIZZOLI R, et al. Does Nutrition plan a role in the prevention and management of sarcopenia [ J ]. Clinical Nutrition, 2018, 37: 1121 1132.). The importance of a "healthier" dietary pattern, which is the need to ingest sufficient protein, vitamin D, antioxidant nutrients and long chain polyunsaturated fatty acids, is pointed out in this article, with a large body of evidence supporting dietary proteins and physical activity as key synthetic stimulators of muscle protein synthesis.
Verreijen et al (VERREIJEN A M, VERLAAN S, ENGBEINK MF, et al. A high blood protein-, leucin-, and vitamin D-expressed present muscles bone protein expression in vivo users adducts: a double-blind regulated controlled three [ J ]. Am J Clin Nutr, 2015, 101: 279 286.) in a double-blind random control trial with a 13 week controlled diet plus exercise for obese elderly (BMI > 30) aged more than 55 years, each of the supplementation consisting of 20g of lactalbumin, 2.8 g of leucine and 1 part of vitamin D after 3 resistive exercises before and after 3 meals a day, the results showed that the high leucine and D protein supplements maintained low muscle mass at SMI and muscle resistance including muscle mass in elderly people (SMI) compared to isocaloric control groups, Muscle strength and function) and thus may reduce the risk of sarcopenia.
Patent CN103766696B discloses a composition with muscle-increasing function, which contains the following components: 30-60 parts of whey protein, 10-30 parts of wheat protein, 5-20 parts of soybean oligopeptide, 1-5 parts of leucine, 60.1-1 parts of vitamin B, 0.001-0.005 part of vitamin D and 0.35-0.8 part of calcium. The composition patent is shown to facilitate protein absorption and utilization by the elderly, promote muscle synthesis, and reduce age-related muscle attenuation. It is known that leucine as a functional food ingredient cannot be applied to ordinary foods, and the muscle-building effect is greatly impaired due to the lack of the support of leucine in the above formula. Meanwhile, the addition amount of the vitamin D is too high, the intake amount of the vitamin D is 10 mug/day according to the diet recommendation of Chinese residents, and the tolerable maximum intake amount is 50 mug/day. According to the patent formula, the vitamin D intake of 20g of the product taken every day is in the range of 200 mug-1000 mug, and far exceeds the tolerable highest intake, excessive vitamin D intake for a long time can cause hypercalcemia, hypercalciuria and the like, the poisoning risk can be increased, and death can be caused due to serious vitamin D poisoning. In addition, the wheat protein contains allergenic components, which are not conducive to digestion and absorption by the human body.
Therefore, it is necessary to search a common health food with obvious muscle protection effect, which is more beneficial for the masses of people to eat at ease.
Disclosure of Invention
Based on the defects of the prior art, the invention discloses a common food which does not contain allergenic components and has obvious muscle protection effect.
In order to achieve the purpose, the invention adopts the technical scheme that:
a composition with muscle protection effect comprises the following raw materials in parts by weight: 11.13-100.09 parts of fermented soybean protein peptide powder, 10.99-98.83 parts of whey protein, 5.08-45.68 parts of prebiotics and 0.31-2.81 parts of mushroom powder, wherein the purity of the mushroom powder is 10%.
As a preferable scheme, the composition comprises the following raw materials in parts by weight: 50.05-100.09 parts of fermented soybean protein peptide powder, 49.42-98.83 parts of whey protein, 22.84-45.68 parts of prebiotics and 1.4-2.81 parts of mushroom powder, wherein the purity of the mushroom powder is 10%.
As a preferred scheme, the fermented soybean protein powder is soybean protein powder with protein content of more than or equal to 80 percent and peptide content of more than or equal to 18 percent.
As a more preferable scheme, the fermented soybean protein powder is prepared by taking soybeans as raw materials, and adopting enzymolysis and fermentation of lactobacillus paracasei and pediococcus pentosaceus composite strains.
Preferably, the prebiotics are inulin, fructo-oligosaccharide or xylo-oligosaccharide.
According to the composition, fermented soybean protein powder and mushroom powder are introduced, the fermented soybean protein powder is rich in multiple nutritional active ingredients such as whole protein, polypeptide, oligopeptide, organic acid and the like through the processes of fermentation and enzymolysis, and the effect of protein supplementation by gradient absorption of multiple nitrogen sources formed by large-molecule whole protein, polypeptide, oligopeptide and amino acid is good; in addition, by combining the enzymolysis composite fermentation technology, the conformational epitope and the linear epitope of the raw material protein allergen can be destroyed, the allergic signal path is weakened, the sensitization risk is effectively reduced, and the zebra fish anaphylactic reaction test proves that the fermented soybean protein peptide powder can not induce anaphylactoid reaction. Meanwhile, mushroom powder raw materials are creatively introduced, and since the mushrooms contain rich lysine which is essential amino acid for human bodies, the mushroom powder can increase the height and the weight and can enhance the disease resistance. Therefore, when the mushroom powder is combined with the fermented soy protein, the lactalbumin and the prebiotics substance, the mushroom powder has obvious synergistic protection effect on the muscle of the human body. In addition, prebiotic nutritional ingredients such as inulin, fructo-oligosaccharide, xylo-oligosaccharide and the like are introduced, so that the negative influence on intestinal microbiota possibly caused by long-term protein supplement is avoided. The raw materials in the formula are common food raw materials, and the food is suitable for all people needing protein supplementation, so that large-scale industrial production can be realized.
Drawings
FIG. 1 is a pathological section of zebrafish test of the compositions prepared in examples 1-3 and comparative examples 1-5 of the present invention.
Detailed Description
Unless otherwise specified, the raw materials used in the examples of the present invention were purchased from the market, the fermented soybean protein peptide powder of the present invention was purchased from biotechnology limited, zhejiang hai, and the fermented soybean protein peptide powder was prepared from isolated soybean protein as a raw material by enzymolysis and fermentation, and the protein content was not less than 80%, and the peptide content was not less than 18%. The mushroom powder is made by self and has the purity of 10 percent.
For better illustrating the objects, technical solutions and advantages of the present invention, the present invention will be further described with reference to specific examples, which are intended to be understood in detail, but not intended to limit the present invention.
The inventive examples 1 to 3 and comparative examples 1 to 5 were weighed according to table 1 and mixed uniformly for use.
Test examples
First, test animal
The zebra fish are all bred in fish breeding water at 28 ℃ (water quality: 200 mg of instant sea salt is added into per 1L of reverse osmosis water, the conductivity is 450-550 muS/cm, the pH is 6.5-8.5, the hardness is 50-100 mg/L CaCO 3), and the license number of experimental animals is as follows: SYXK (Zhe) 2012-0171. The feeding management meets the requirements of the international AAALAC certification (certification number: 001458).
Wild type AB line zebrafish, bred by natural pairwise mating, aged 2 days after fertilization (2 dpf).
Second, instrument, consumable and reagent
2.1 instruments
Biomicroscopes (CX 31, OLYMPUS, Japan); dissecting microscopes (SZX 7, OLYMPUS, Japan); precision electronic balances (CP 214, OHAUS, USA); 6-well plates (Nest Biotech, China).
Second, instrument, consumable and reagent
4% tissue cell fixative (batch No. 20190923, Solarbio); xylene (batch No. C10631736, shanghai mclin biochem technologies ltd.); PBS buffer (batch No. 10C16B30, Wuhan doctor De bioengineering Co., Ltd.); mayer hematoxylin staining solution (batch No. YH0170326, shanghai ihh biotechnology limited); eosin staining solution (batch No. YH180124, ihh biotechnology ltd, shanghai); neutral resin coated tablets (batch No. YH0170419, ihhe biotechnology limited, shanghai); soft wax (melting point 54-56 ℃, batch number 20180108, Shanghai Huayong Paraffin Co., Ltd.); hard wax (melting point 62-64 ℃, batch number 20190628, Shanghai Huayong Paraffin Co., Ltd.); absolute ethanol (batch No. 20200104, national pharmaceutical group chemical Co., Ltd., China).
Third, test method
3.1. Experimental groups
3.2. Test method
Evaluation of sample muscle protection efficacy (pathological section)
240 tail 2 dpf wild type AB strain zebra fish were randomly selected in six-well plates, and 30 tail zebra fish were treated per well (experimental group). Except for a normal control group, all the other experimental groups are dissolved in water and are given 1.5 percent of absolute ethyl alcohol for 24 hours to establish a zebra fish alcoholic muscle injury model. Samples were separately dosed in water at the concentrations indicated in the above table, while a normal control group and a model control group were set at a volume of 3 mL per well. After 24H treatment at 28 ℃, zebrafish were fixed with 4% tissue cell fixative, H & E stained (fix-dehydrate-embed-slice-stain) and pathologically analyzed for sample muscle protection efficacy. The samples were scored for muscle protection efficacy according to table 2.
Remarking: normal score 0, mild muscle damage score 1-4, moderate muscle damage score 5-6, and severe muscle damage score 7-8.
Fourth, test results
The length, infiltration degree and necrosis degree of the muscles of all groups are 0. The results of the summary of the clarity and the relaxation are shown in Table 3, and the pathological section is shown in FIG. 1.
Test remarks:
& is relative to the mock control group, # is relative to the equivalent concentration protein + inulin group (example 1 group versus the comparative example 2 group, example 2 group versus the comparative example 4 group) # is relative to the comparative example 5.
2. Three identical symbols indicate p < 0.001, two identical symbols indicate p < 0.01, and are extremely significant, and one identical symbol indicates p < 0.05, and significantly, the smaller the p value, the more significant the difference.
3.0 for normal, 1-4 for mild muscle damage, 5-6 for moderate muscle damage, and 7-8 for severe muscle damage.
As can be seen from Table 4:
the model control group has extremely significant difference compared with the normal control group, which indicates that the molding is successful. There was no significant difference between the comparative example 1 group and the comparative example 3 group relative to the model control group, indicating that mushroom powder in this concentration range had no muscle-protecting efficacy. The comparative example 2 group and the comparative example 4 group have significant difference relative to the model control group, which shows that the protein + inulin group has protective effect on the muscle, and the severe muscle damage of the model group is reduced to moderate damage. The groups 1-3 had very significant differences compared to the model control group, indicating that the test group had significant muscle protection.
The groups of example 1 and example 2 have significant differences relative to the groups of protein and inulin (comparative example 2 and comparative example 4) at the same concentration, which shows that the mushroom powder groups (comparative example 1 and comparative example 2) and the groups of protein and inulin (comparative example 2 and comparative example 4) have synergistic effects, severe muscle damage in the model group can be reduced to mild damage, and the muscle protection effect is obvious. Example 3 has a very significant difference with respect to comparative example 5 (same total concentration), indicating that the experimental formulation has a better muscle protection efficacy than comparative example 5.
Claims (5)
1. The composition with the muscle protection effect is characterized by comprising the following raw materials in parts by weight: 11.13-100.09 parts of fermented soybean protein peptide powder, 10.99-98.83 parts of whey protein, 5.08-45.68 parts of prebiotics and 0.31-2.81 parts of mushroom powder, wherein the purity of the mushroom powder is 10%.
2. The composition according to claim 1, comprising the following raw materials in parts by weight: 50.05-100.09 parts of fermented soybean protein peptide powder, 49.42-98.83 parts of whey protein, 22.84-45.68 parts of prebiotics and 1.4-2.81 parts of mushroom powder, wherein the purity of the mushroom powder is 10%.
3. The composition according to claim 1 or 2, characterized in that: the fermented soybean protein powder is soybean protein powder with protein content more than or equal to 80% and peptide content more than or equal to 18%.
4. The composition according to claim 1 or 2, characterized in that: the fermented soybean protein powder is prepared by taking soybeans as raw materials, and adopting directional enzymolysis and fermentation of lactobacillus paracasei and pediococcus pentosaceus composite strains.
5. The composition according to claim 1 or 2, characterized in that: the prebiotics are inulin, fructo-oligosaccharide or xylo-oligosaccharide.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011511533.8A CN112544989A (en) | 2020-12-18 | 2020-12-18 | A composition with muscle protecting effect |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011511533.8A CN112544989A (en) | 2020-12-18 | 2020-12-18 | A composition with muscle protecting effect |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112544989A true CN112544989A (en) | 2021-03-26 |
Family
ID=75030506
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011511533.8A Pending CN112544989A (en) | 2020-12-18 | 2020-12-18 | A composition with muscle protecting effect |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112544989A (en) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101455332A (en) * | 2009-01-14 | 2009-06-17 | 岳邦珅 | Edible fungus composition capable of preventing and controlling disease |
| CN103053950A (en) * | 2013-01-12 | 2013-04-24 | 胡玮 | Method for fermenting soybean by virtue of lactobacillus |
| CN105475487A (en) * | 2015-12-09 | 2016-04-13 | 中国农业大学 | Preparation method of ginkgo protein peptide fermented milk and ginkgo protein peptide fermented milk beverage |
| CN106072573A (en) * | 2016-07-05 | 2016-11-09 | 郑州和正生物科技有限公司 | A kind of it is applicable to the special dietary seafood that old aged muscle decay disease is edible |
| CN106259946A (en) * | 2016-08-23 | 2017-01-04 | 江苏朸健生命科技发展有限公司 | A kind of sport nutrition solid beverage and preparation method thereof |
| US20170020926A1 (en) * | 2014-04-01 | 2017-01-26 | Rubius Therapeutics, Inc. | Methods and compositions for immunomodulation |
| CN106722878A (en) * | 2016-12-11 | 2017-05-31 | 昭平县科学技术指导站 | A kind of edible fungi nutrition powder |
-
2020
- 2020-12-18 CN CN202011511533.8A patent/CN112544989A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101455332A (en) * | 2009-01-14 | 2009-06-17 | 岳邦珅 | Edible fungus composition capable of preventing and controlling disease |
| CN103053950A (en) * | 2013-01-12 | 2013-04-24 | 胡玮 | Method for fermenting soybean by virtue of lactobacillus |
| US20170020926A1 (en) * | 2014-04-01 | 2017-01-26 | Rubius Therapeutics, Inc. | Methods and compositions for immunomodulation |
| CN105475487A (en) * | 2015-12-09 | 2016-04-13 | 中国农业大学 | Preparation method of ginkgo protein peptide fermented milk and ginkgo protein peptide fermented milk beverage |
| CN106072573A (en) * | 2016-07-05 | 2016-11-09 | 郑州和正生物科技有限公司 | A kind of it is applicable to the special dietary seafood that old aged muscle decay disease is edible |
| CN106259946A (en) * | 2016-08-23 | 2017-01-04 | 江苏朸健生命科技发展有限公司 | A kind of sport nutrition solid beverage and preparation method thereof |
| CN106722878A (en) * | 2016-12-11 | 2017-05-31 | 昭平县科学技术指导站 | A kind of edible fungi nutrition powder |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105792837B (en) | Composition comprising collagen peptide, elastin peptide and proteoglycan | |
| CN105265811B (en) | A kind of additive increasing pork lean meat percentage and flavor | |
| KR20100057630A (en) | Amino acid and peptide products | |
| JP6205616B2 (en) | Beautiful skin promoter and its use | |
| Shittu et al. | Growth performance and haematological and serum biochemical parameters of broiler chickens given varied concentrations of Polyalthia longifolia leaf extract in place of conventional antibiotics | |
| CN107691952A (en) | A kind of resisting kinetic fatigue, the composition for promoting postexercise recovery and preparation method thereof | |
| CN113398144B (en) | Application of nucleotide mixture in preparation of preparation for preventing or relieving sarcopenia of old people | |
| CN102512655A (en) | L-carnitine composition, L-carnitine preparation and preparation method and application thereof | |
| CN109602021A (en) | Nutraceutical containing sialic acid | |
| US20120309716A1 (en) | Motor Function Improver | |
| CN1843156A (en) | Purple common perilla seed feedstuff additive and preparation method thereof | |
| Liu et al. | Effects of supplemented culture media from solid-state fermented Isaria cicadae on performance, serum biochemical parameters, serum immune indexes, antioxidant capacity and meat quality of broiler chickens | |
| KR20190090715A (en) | An animal feed composition comprising phlorotannin and product for animal | |
| CN109007343A (en) | A kind of compound feed additive and preparation method thereof of anti-beef cattle transport stress | |
| EP2127540A1 (en) | Skin-beautifying agent | |
| RU2366271C1 (en) | Forage additive as preventive and treatment medium for domestic and farm animals | |
| EP1897551A1 (en) | Health food and pharmaceutical composition for amelioration of disease induced by metabolic disorder in cartilage | |
| CN114903128B (en) | Crayfish compound feed and preparation method thereof | |
| CN112544989A (en) | A composition with muscle protecting effect | |
| Chen et al. | Effects of Ligustrum lucidum fruits on growth performance, antioxidation and meat quality in arbor acres broilers | |
| Wang et al. | Structural properties, anti-fatigue and immunological effect of low molecular weight peptide from Monkfish | |
| CN108285850A (en) | A kind of liver-protecting white spirit and preparation method thereof | |
| CN107668348A (en) | A kind of compound additive for improving intestine of young pigs health and preparation method and application | |
| CN114190561A (en) | Microencapsulated royal jelly enzymolysis polypeptide, preparation method thereof and solid powder containing microencapsulated royal jelly enzymolysis polypeptide | |
| CN106942652A (en) | It is a kind of to improve immunity, strengthen the health-preserving food of resistance against diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |